A clinical trial now open at UW Health | Carbone Cancer Center uses a patient’s dying tumor cells to try to teach their immune system to find and destroy cancer cells following surgery for a type of brain cancer called glioblastoma.
Carbone Cancer Center is one of about two dozen cancer centers testing a new investigational immunotherapy approach to treating one of the deadliest cancers.
Glioblastoma tends to recur and patients live, on average, only 15 months after diagnosis and treatment with brain surgery, radiation and chemotherapy. However, a subset of patients in a phase 1b clinical trial of this approach, which was designed to test the safety of the treatment, lived an average of 38 months when they received the highest dose of immunotherapy. The phase 2b clinical trial plans to enroll 93 newly diagnosed patients.
;
